Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iva Gunnarsson

Showing results (31-40 of 192) with videos related to

Pageof 20
Sort By:
Clinical and Experimental Immunology|October 8, 2025
Interleukin 16 in lupus nephritis-a role for Th1 and CD8+ T cell migrationKittikorn Wangriatisak, Francesca Faustini, Masa Filipovic, et al.
Clinical Immunology (Orlando, Fla.)|January 27, 2020
The binding of SLE autoantibodies to mitochondriaDavid S Pisetsky, Diane M Spencer, Fariborz Mobarrez, et al.
British Journal of Haematology|May 19, 2025
Anti-HSP90α IgG may protect against antiphospholipid syndrome in systemic lupus erythematosus by reducing platelet activationMarina Barguil Macêdo, Andreas Jönsen, Anders A Bengtsson, et al.
Frontiers in Immunology|October 18, 2021
Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide StudyTomas Walhelm, Iva Gunnarsson, Rebecca Heijke, et al.
Arthritis and Rheumatism|September 18, 2003
Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosusElisabet Svenungsson, Iva Gunnarsson, Guo-Zhong Fei, et al.
Lupus Science & Medicine|July 22, 2021
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control studyIsak Samuelsson, Ioannis Parodis, Iva Gunnarsson, et al.
Arthritis Research & Therapy|May 1, 2019
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosusVilija Oke, Iva Gunnarsson, Jessica Dorschner, et al.
Journal of Autoimmunity|May 20, 2019
Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexesFariborz Mobarrez, Enrico Fuzzi, Iva Gunnarsson, et al.
Arthritis Research & Therapy|February 22, 2012
Renal expression and serum levels of high mobility group box 1 protein in lupus nephritisAgneta Zickert, Karin Palmblad, Birgitta Sundelin, et al.
Arthritis Research & Therapy|November 10, 2006
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritisTherese Vallerskog, Mikael Heimbürger, Iva Gunnarsson, et al.
Pageof 20

Showing results (31-40 of 192) with videos related to

Sort By:
Pageof 20
Clinical and Experimental Immunology|October 8, 2025
Interleukin 16 in lupus nephritis-a role for Th1 and CD8+ T cell migrationKittikorn Wangriatisak, Francesca Faustini, Masa Filipovic, et al.
Clinical Immunology (Orlando, Fla.)|January 27, 2020
The binding of SLE autoantibodies to mitochondriaDavid S Pisetsky, Diane M Spencer, Fariborz Mobarrez, et al.
British Journal of Haematology|May 19, 2025
Anti-HSP90α IgG may protect against antiphospholipid syndrome in systemic lupus erythematosus by reducing platelet activationMarina Barguil Macêdo, Andreas Jönsen, Anders A Bengtsson, et al.
Frontiers in Immunology|October 18, 2021
Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide StudyTomas Walhelm, Iva Gunnarsson, Rebecca Heijke, et al.
Arthritis and Rheumatism|September 18, 2003
Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosusElisabet Svenungsson, Iva Gunnarsson, Guo-Zhong Fei, et al.
Lupus Science & Medicine|July 22, 2021
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control studyIsak Samuelsson, Ioannis Parodis, Iva Gunnarsson, et al.
Arthritis Research & Therapy|May 1, 2019
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosusVilija Oke, Iva Gunnarsson, Jessica Dorschner, et al.
Journal of Autoimmunity|May 20, 2019
Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexesFariborz Mobarrez, Enrico Fuzzi, Iva Gunnarsson, et al.
Arthritis Research & Therapy|February 22, 2012
Renal expression and serum levels of high mobility group box 1 protein in lupus nephritisAgneta Zickert, Karin Palmblad, Birgitta Sundelin, et al.
Arthritis Research & Therapy|November 10, 2006
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritisTherese Vallerskog, Mikael Heimbürger, Iva Gunnarsson, et al.
Pageof 20